» Articles » PMID: 37511989

Cerebral Vasomotor Reactivity in COVID-19: A Narrative Review

Overview
Journal Life (Basel)
Specialty Biology
Date 2023 Jul 29
PMID 37511989
Authors
Affiliations
Soon will be listed here.
Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) primarily affects the respiratory system but can also lead to neurological complications. Among COVID-19 patients, the endothelium is considered the Achilles heel. A variety of endothelial dysfunctions may result from SARS-CoV-2 infection and subsequent endotheliitis, such as altered vascular tone, oxidative stress, and cytokine storms. The cerebral hemodynamic impairment that is caused is associated with a higher probability of severe disease and poor outcomes in patients with COVID-19. This review summarizes the most relevant literature on the role of vasomotor reactivity (VMR) in COVID-19 patients. An overview of the research articles is presented. Most of the studies have supported the hypothesis that endothelial dysfunction and cerebral VMR impairment occur in COVID-19 patients. Researchers believe these alterations may be due to direct viral invasion of the brain or indirect effects, such as inflammation and cytokines. Recently, researchers have concluded that viruses such as the Human Herpes Virus 8 and the Hantavirus predominantly affect endothelial cells and, therefore, affect cerebral hemodynamics. Especially in COVID-19 patients, impaired VMR is associated with a higher risk of severe disease and poor outcomes. Using VMR, one can gain valuable insight into a patient's disease progression and make more informed decisions regarding appropriate treatment options. A new pandemic may develop with the COVID-19 virus or other viruses, making it essential that healthcare providers and researchers remain focused on developing new strategies for improving survival in such patients, particularly those with cerebrovascular risk factors.

Citing Articles

Cerebrovascular Reactivity Assessed by Breath-Hold Functional MRI in Patients with Neurological Post-COVID-19 Syndrome-A Pilot Study.

Zerweck L, Klose U, Mengel A, Hoheisel T, Eikemeier M, Richter V Neurol Int. 2024; 16(5):992-1004.

PMID: 39311348 PMC: 11417792. DOI: 10.3390/neurolint16050075.


Morphology and Function of Red Blood Cells in COVID-19 Patients: Current Overview 2023.

Jung F, Connes P Life (Basel). 2024; 14(4).

PMID: 38672731 PMC: 11051426. DOI: 10.3390/life14040460.


SARS-CoV-2 and Brain Health: New Challenges in the Era of the Pandemic.

Ahmed W, Feng J, Zhang Y, Chen L Microorganisms. 2023; 11(10).

PMID: 37894169 PMC: 10609574. DOI: 10.3390/microorganisms11102511.

References
1.
Silva M, Ribeiro L, Gouveia M, Marcelino B, Dos Santos C, Lima K . Hyperinflammatory Response in COVID-19: A Systematic Review. Viruses. 2023; 15(2). PMC: 9962879. DOI: 10.3390/v15020553. View

2.
Chang R, Mamun A, Dominic A, Le N . SARS-CoV-2 Mediated Endothelial Dysfunction: The Potential Role of Chronic Oxidative Stress. Front Physiol. 2021; 11:605908. PMC: 7844210. DOI: 10.3389/fphys.2020.605908. View

3.
Cohen A, Wang Y . Improving the Assessment of Breath-Holding Induced Cerebral Vascular Reactivity Using a Multiband Multi-echo ASL/BOLD Sequence. Sci Rep. 2019; 9(1):5079. PMC: 6434035. DOI: 10.1038/s41598-019-41199-w. View

4.
Novaes N, Sadik R, Sadik J, Obadia M . Epidemiology and Management of Cerebral Venous Thrombosis during the COVID-19 Pandemic. Life (Basel). 2022; 12(8). PMC: 9332165. DOI: 10.3390/life12081105. View

5.
Mathioudakis A, Fally M, Hashad R, Kouta A, Hadi A, Knight S . Outcomes Evaluated in Controlled Clinical Trials on the Management of COVID-19: A Methodological Systematic Review. Life (Basel). 2020; 10(12). PMC: 7765224. DOI: 10.3390/life10120350. View